These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6786673)

  • 1. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis.
    Memmos DE; Eastwood JB; Talner LB; Gower PE; Curtis JR; Phillips ME; Carter GD; Alaghband-Zadeh J; Roberts AP; de Wardener HE
    Br Med J (Clin Res Ed); 1981 Jun; 282(6280):1919-24. PubMed ID: 6786673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
    el-Reshaid K; el-Reshaid W; Sugathan T; al-Mohannadi S; Sivanandan R
    Am J Nephrol; 1997; 17(6):505-10. PubMed ID: 9426846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients.
    Sharman VL; Abrams SM; Adami S; Cattell WR; Chaput de Saintonge DM; Greenwood RN; Goodwin FJ; Hately W; Hattersley LA; Marsh FP; Morgan AG; Muir JW; O'Riordan JL; Papapoulos SE; Revell P; Tucker AK; Baker LR
    Proc Eur Dial Transplant Assoc; 1983; 19():287-92. PubMed ID: 6348740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
    Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis.
    Berl T; Berns AS; Huffer WE; Alfrey AC; Arnaud CD; Schrier RR
    Contrib Nephrol; 1980; 18():72-81. PubMed ID: 6243528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism.
    Lind L; Wengle B; Sørensen OH; Wide L; Akerström G; Ljunghall S
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):250-6. PubMed ID: 2644746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1,25(OH)2vitamin D3.
    Muramoto H; Haruki K; Yoshimura A; Mimo N; Oda K; Tofuku Y
    Nephron; 1991; 58(3):288-94. PubMed ID: 1896093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
    Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
    Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
    Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitriol in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
    Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients.
    Winney RJ; Tothill P; Robson JS; Abbot SR; Lidgard GP; Cameron EH; Smith MA; Macpherson HN; Strong JA
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():151s-158s. PubMed ID: 606413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
    Coyne DW; Grieff M; Ahya SN; Giles K; Norwood K; Slatopolsky E
    Am J Kidney Dis; 2002 Dec; 40(6):1283-8. PubMed ID: 12460048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled trial of calcitriol in hemodialysis patients.
    Baker LR; Muir JW; Sharman VL; Abrams SM; Greenwood RN; Cattell WR; Goodwin FJ; Marsh FP; Adami S; Hately W
    Clin Nephrol; 1986 Oct; 26(4):185-91. PubMed ID: 3536232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism in patients on hemodialysis.
    Pecovnik-Balon B
    Am J Nephrol; 1995; 15(5):401-6. PubMed ID: 7503139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of effect of 24,25-dihydroxyvitamin D3 in primary hyperparathyroidism.
    Netelenbos JC; Asscheman H; Lips P; Van der Vijgh WJ; Jongen MJ; Van Ginkel F; Hackeng WH
    J Clin Endocrinol Metab; 1986 Jul; 63(1):246-8. PubMed ID: 3486877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.